Company intelligence / Profile preview

Hav Art

Ownership: Private
Development stage: Other

Overview

ARTBIO is developing a new class of alpha radioligand therapies for cancer. The company’s approach leverages deep expertise in cancer biology and isotope production, aiming for high affinity/selectivity agents that effectively kill tumors while sparing healthy tissue. No published clinical results yet; focus remains on R&D and pipeline development.

Therapeutic areas: Oncology
Modalities: Radioligand therapyAlpha radioligand therapy
Industry: Biotech

Partnerships

3B Pharmaceuticals (licensing and research partnership to advance first-in-class alpha radioligand therapy for solid tumors)F-Prime teamRadforsk

Beyond the preview

Go deeper on Hav Art.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hav Art.

Explore the full profile